Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, is a company that specializes in innovative ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

The US Supreme Court rejected a case asking the justices to interpret a patent-infringement safe-harbor provision in a ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The ...

Citi analyst Joanne Wuensch maintained a Buy rating on Edwards Lifesciences (EW – Research Report) today. The company’s shares closed yesterday ...

Zacks Research raised their FY2024 earnings per share (EPS) estimates for Edwards Lifesciences in a research note issued on ...

Critical Care Divestment Fuels Structural Heart Opportunities: On Sept. 3, 2024, Edwards Lifesciences completed ... for a fourth and larger size EVOQUE valve — 56 millimeters.

Edwards Lifesciences Corp. engages ... Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through ...